[Effect of low-dose triptorelin on pituitary down-regulation for patients undergoing in vitro fertilization and embryo transfer].
OBJECTIVE
To observe the effect of low-dose triptorelin in later luteal phase on pituitary down-regulation for patients undergoing IVF-ET.


METHODS
One hundred and twenty patients were randomly divided into 2 groups(A and B). In group A, the patients were treated with triptorelin of 0.1 mg subcutaneously daily started on day 21 of menstrual cycle for 7 days. In group B, the patients were treated with long protocol of Buserelin intranasal spray. Comparisons were made between the groups in serum concentrations of FSH, LH, E2, T, PRL and P on the third day (D3) of superovulation cycle and on the day of hCG administration, highly purified follicle-stimulating hormone (HP) dosages, and so on.


RESULTS
In group A, mean serum LH level on D3 and the day of hCG was (1.55 +/- 0.99) U/L and (2.70 +/- 1.45) U/L, E2 was (85.66 +/- 13.13) pmol/L and (5,451.31 +/- 1,900.61) pmol/L, respectively, significantly lower than those of group B (P < 0.001; P < 0.01; P < 0.05; P < 0.001). Mean HP(75 IU/Amp) dosage per treatment cycle in group A was 28.20 +/- 11.03 ampoules, significantly higher than 22.30 +/- 6.40 ampoules in group B(P < 0.001).


CONCLUSIONS
Low-dose triptorelin in later luteal phase is effective for down-regulation of pituitary and produces more suppression on endogenous LH in pituitary than Buserelin long protocol.
D000328:Adult; D015536:Down-Regulation; D004624:Embryo Transfer; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D007279:Injections, Subcutaneous; D007986:Luteinizing Hormone / Q000097:blood; D008186:Luteolytic Agents / Q000008:administration & dosage*; D010902:Pituitary Gland / Q000187:drug effects / Q000502:physiology*; D017329:Triptorelin Pamoate / Q000008:administration & dosage*
D008186:Luteolytic Agents; D017329:Triptorelin Pamoate; D004958:Estradiol; D007986:Luteinizing Hormone